Volume 60, Issue 1 pp. 264-268
Autoinflammatory Disease

Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): An unrecognized autoinflammatory disease?

Paolo Picco

Corresponding Author

Paolo Picco

G. Gaslini Institute, and University of Genoa, Genoa, Italy

UO Pediatria II, Istituto G. Gaslini, Largo G. Gaslini 5, 16145 Genoa, ItalySearch for more papers by this author
Giacomo Brisca

Giacomo Brisca

G. Gaslini Institute, and University of Genoa, Genoa, Italy

Search for more papers by this author
Francesco Traverso

Francesco Traverso

G. Gaslini Institute, and University of Genoa, Genoa, Italy

Search for more papers by this author
Anna Loy

Anna Loy

G. Gaslini Institute, and University of Genoa, Genoa, Italy

Search for more papers by this author
Marco Gattorno

Marco Gattorno

G. Gaslini Institute, and University of Genoa, Genoa, Italy

Search for more papers by this author
Alberto Martini

Alberto Martini

G. Gaslini Institute, and University of Genoa, Genoa, Italy

Search for more papers by this author
First published: 30 December 2008
Citations: 132

Abstract

Recurrent pericarditis occurs in association with various medical conditions, but in most cases the condition appears to be idiopathic. Although high-dose steroid treatment is often effective, it may have serious side effects. Herein we describe 3 children with recurrent pericarditis who were treated at our hospital, during flares, with the interleukin-1β receptor antagonist anakinra, with immediate response. Pericarditis recurred when anakinra treatment was discontinued, and no further episodes occurred after it was resumed. Idiopathic recurrent pericarditis shares several features with autoinflammatory diseases, and anakinra has been efficacious in the treatment of the latter diseases. The findings in these patients suggest that idiopathic recurrent pericarditis may be a previously unrecognized autoinflammatory disease.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me